Literature DB >> 8198379

Natural history of autosomal dominant polycystic kidney disease.

G M Fick1, P A Gabow.   

Abstract

At least two different genes, which have been mapped to chromosomes 4 and 16, cause autosomal dominant polycystic kidney disease, a disorder with renal and extrarenal manifestations. Although gene-linkage testing is possible, the disease is diagnosed mainly through ultrasonography. Renal disease is characterized clinically by hypertension, acute and chronic pain, and variable progression to end-stage renal disease. Extrarenal manifestations include liver cysts, which may lead to complications; ruptured intracranial aneurysms; cardiac valvular disease; colonic diverticula; and inguinal hernias. Disease management is directed at minimizing and treating the complications of this illness.

Entities:  

Mesh:

Year:  1994        PMID: 8198379     DOI: 10.1146/annurev.med.45.1.23

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  12 in total

1.  Renal function and healthcare costs in patients with polycystic kidney disease.

Authors:  Krista L Lentine; Huiling Xiao; Gerardo Machnicki; Adrian Gheorghian; Mark A Schnitzler
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  Ruptured sinus of Valsalva aneurysm in a patient with autosomal dominant polycystic kidney disease.

Authors:  R F Sprung; R M Cataldo; M C Gregory; M L Marks; D A Bull; S E Litwin
Journal:  West J Med       Date:  1996-12

Review 3.  Diagnosis and management of polycystic liver disease.

Authors:  Tom J G Gevers; Joost P H Drenth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

4.  Ruptured sinus of a Valsalva aneurysm associated with autosomal-dominant polycystic kidney disease in an elderly patient: report of a case.

Authors:  T Saito; A Mishima; M Asano; S Yamamoto; S Sasaki; T Saeki; T Manabe
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

Review 5.  Management of polycystic liver disease.

Authors:  Gregory T Everson; Matthew R G Taylor
Journal:  Curr Gastroenterol Rep       Date:  2005-02

6.  Colonic diverticular disease in autosomal dominant polycystic kidney disease: is there really an association? A nationwide analysis.

Authors:  Rodrigo Duarte-Chavez; Jill Stoltzfus; Vikas Yellapu; Noel Martins; Sudip Nanda; Santo Longo; Berhanu Geme; Yecheskel Schneider
Journal:  Int J Colorectal Dis       Date:  2020-09-01       Impact factor: 2.571

7.  Apoptosis and autophagy in polycystic kidney disease (PKD).

Authors:  Kristen L Nowak; Charles L Edelstein
Journal:  Cell Signal       Date:  2019-12-24       Impact factor: 4.315

Review 8.  Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions.

Authors:  R E Simoni; L N L Ferreira Gomes; F B Scalco; C P H Oliveira; F R Aquino Neto; M L Costa de Oliveira
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

9.  Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.

Authors:  Tom J G Gevers; Melissa Chrispijn; Jack F M Wetzels; Joost P H Drenth
Journal:  BMC Nephrol       Date:  2012-04-04       Impact factor: 2.388

Review 10.  Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development.

Authors:  Xiying Lin; Jiayu Tang; Yan-Ru Lou
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.